On November 4, 2021 City of Hope reported that it will present new research on bispecific antibodies at a press briefing during the ASH (Free ASH Whitepaper) 63rd Annual Meeting and Exposition on Dec. 11 to 14 in Atlanta (Press release, City of Hope, NOV 4, 2021, View Source [SID1234594538]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Other innovative City of Hope research on stem cell transplants and blood cancer treatments will also be presented during the conference organized by ASH (Free ASH Whitepaper). ASH (Free ASH Whitepaper) is the world’s largest professional society for clinicians and scientists around the world who are working on blood cancers and other hematological diseases.

City of Hope is finding new treatments for some of the hardest to treat cancers by accelerating innovative clinical research and therapies. The comprehensive cancer center’s bone marrow transplant program is one of the largest and most successful in the nation and its chimeric antigen receptor (CAR) T cell therapy program is also focused on finding new therapies. City of Hope is leading other innovative immunotherapy treatments for blood cancers.

Elizabeth Budde, M.D, Ph.D., associate professor, City of Hope Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, will present research on a bispecific antibody — mosunetuzumab — for relapsed/refractory follicular lymphoma at an ASH (Free ASH Whitepaper) press briefing titled "Immune System 1, Cancer 0: Advances in Immunotherapy" on Saturday, Dec. 11 at 8:30 a.m. ET Follicular lymphoma is associated with frequent relapses and decreasing progression-free intervals with successive lines of conventional therapy. Later-line treatments may be less effective due to refractory disease. Mosunetuzumab is a CD20xCD3 bispecific antibody that redirects T cells to eliminate malignant B cells. In the dose-escalation phase of an ongoing Phase I/II study (NCT02500407), Mosunetuzumab was highly active and well tolerated in R/R FL patients (pts).

Dr. Budde will also present the research at a plenary session.

Title: Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Publication Number: 127
Type: Oral
Session Name: 623. Mantle Cell, Follicular and Other B Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B Cell Lymphomas
Session Date and Time: Saturday, Dec. 11, 2021, Noon to 1:30 p.m. ET
Presentation Time: Saturday, Dec. 11, 2021, Noon ET

During the ASH (Free ASH Whitepaper) conference, additional City of Hope researchers will also make presentations onsite or virtually:

Title: Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade
Publication Number: 234
Type: Oral.
Session Name: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials
Session Date and Time: Saturday, Dec. 11, 2021, 2 to 3:30 p.m. ET
Presentation Time: Saturday, Dec. 11, 2021, 3:15 p.m. ET
Presenter: Alex Herrera, M.D., associate professor, City of Hope Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation

Herrera will also introduce an abstract at a plenary scientific session on Sunday, Dec. 12, 2 to 4 p.m. ET

Title: A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation
Publication Number: 334
Type: Oral
Session Name: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Infection and Immune Reconstitution
Session Date and Time: Saturday, Dec. 11, 2021, 4 to 5:30 p.m. ET
Presentation Time: Saturday, Dec. 11, 2021, 4:45 p.m. ET
Presenter: Karamjeet S. Sandhu, M.D., assistant professor, City of Hope Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation

Title: The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Publication Number: 417
Type: Oral
Session Name: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Prognostic Biomarkers for Donor Selection and Recipient Outcomes
Session Date and Time: Sunday, Dec. 12, 2021, 9:30 a.m. to 11 a.m. ET
Presentation Time: Sunday, Dec. 12, 2021, 10 a.m. ET
Presenter: Matthew G. Mei, M.D., associate professor, City of Hope Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation

In addition, Andrew Artz, M.D., M.S., professor, City of Hope Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, will speak at an education session titled "How Can We Ensure That Everyone Who Needs a Transplant Can Get One?" about allogeneic hematopoietic cell transplantation for older adults and will also give opening remarks a scientific workshop on hematology and aging.